Innovative Therapeutics Sigilon Therapeutics specializes in developing immune-protected, engineered human cell therapies aimed at providing functional cures for acute and chronic diseases, representing a unique opportunity for partners interested in cell-based treatment platforms.
Strong Industry Ties The company has a history of successful collaboration with Eli Lilly since 2018 and was acquired by Lilly in 2023 for $310M, indicating confidence in their technology and potential for strategic partnership or investment opportunities.
Technological Edge Sigilon's focus on encapsulated-cell therapies, particularly for conditions like type 1 diabetes, presents a differentiation point that may attract collaborations with organizations seeking advanced biological delivery systems or proprietary cell encapsulation technologies.
Financial Growth Potential With current revenues estimated between $10M and $50M and over $145M in funding, there are significant growth opportunities for investors and partners to support the expansion of their innovative therapeutic pipeline.
Market Expansion Given their focus on developing treatments for a broad spectrum of acute and chronic diseases, there is potential for sales expansion into multiple therapeutic areas and markets, especially with their recent acquisition by a major industry player.
Sigilon, Inc. uses 8 technology products and services including Akamai, WordPress, Babel, and more. Explore Sigilon, Inc.'s tech stack below.
| Sigilon, Inc. Email Formats | Percentage |
| First.Last@sigilon.com | 85% |
| FLast@sigilon.com | 13% |
| First@sigilon.com | 2% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Sigilon Therapeutics', a wholly owned subsidiary of Eli Lilly and Company, mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
Company Overview
Media & News
Funding & FinancialsSigilon, Inc. has raised a total of $145M of funding over 4 rounds. Their latest funding round was raised on Dec 03, 2020 in the amount of $145M.
Sigilon, Inc.'s revenue is estimated to be in the range of $10M$25M
Funding & FinancialsSigilon, Inc. has raised a total of $145M of funding over 4 rounds. Their latest funding round was raised on Dec 03, 2020 in the amount of $145M.
Sigilon, Inc.'s revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com